Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Epilepsy Foundation Pipeline Conference to Feature Winners of the SUDEP Challenge on Identifying Biomarkers Predicting Sudden Unexpected Death in Epilepsy (SUDEP) | ||
By: Nasdaq / GlobeNewswire - 15 Feb 2018 | Back to overview list |
|
LANDOVER, Md., Feb. 15, 2018 (GLOBE NEWSWIRE) -- The Epilepsy Foundation Pipeline Conference will feature the winners of the SUDEP Institute’s 2nd milestone of its fourth challenge, “Developing Predictive Biomarkers of Epilepsy Seizures.” This is part of the fourth and final challenge, in partnership with InnoCentive, that will ultimately award more than $1 million in prizes. Each year, more than 1 in 1,000 adults and 1 in 4,500 children with epilepsy die from SUDEP, or sudden unexpected death in epilepsy. If seizures are uncontrolled, the risk of SUDEP increases to more than 1 out of 150. “There are few interventions that reliably predict and prevent SUDEP in people with epilepsy. Identifying biomarkers to predict SUDEP is a major unmet medical need,” said Director of the SUDEP Institute Sally Schaeffer. “The SUDEP Institute is eagerly spearheading this biomarker challenge to develop a therapeutic intervention for those at risk. As the new director of the SUDEP Institute and, most importantly, a parent who has lost a child to SUDEP, I am looking forward to the next milestone in the challenge.” The purpose of the SUDEP Institute challenge is to harness interdisciplinary approaches and alternative perspectives in the science community to find solutions to the SUDEP puzzle. “It was a privilege to participate with expert colleagues in the field to critically review the applications submitted to SUDEP to determine biomarkers that could identify the likelihood of these terrible outcomes before they occur,” said Holli Hamilton MD, MPH, Senior Medical Officer, National Center for Advancing Translational Sciences, National Institutes of Health. “Requiring that the many proposed approaches be inexpensive, rapid and serve as a prognostic biomarker was a challenging benchmark.” Four winners were each awarded $25,000.
The winners will present their findings at the Epilepsy Foundation Pipeline Conference February 22-23, 2018, in San Francisco, CA. The conference will bring together decision makers with a stake in the field of epilepsy treatment, therapeutic innovation, and product development. The third milestone requires results that demonstrates the predictive efficacy of the biomarker(s). Submissions will be accepted until October 17, 2020 and reviewed as they are submitted. The first submission that meets all the challenge criteria will receive the final award of $800,000. About Epilepsy and SUDEP “Like” the Epilepsy Foundation on Facebook at facebook.com/epilepsyfoundationofamerica and follow us on Twitter at twitter.com/epilepsyfdn. About the Epilepsy Foundation SUDEP Institute Contact |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |